active long
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nidan.... the Alzheimer's world is suffering from a lack of oxygen from the headlines:
"Roche and Biogen temper Alzheimer expectations in Q2 call, will Lilly follow suit in August"
"After failing Alzheimer's launch, Biogen writes off the remaining value of its Aduhelm inventory"
It seems just the right time for us to present the P2/3 data for 2-73. Probably wasn't planned, but it'll work!
sab63090 our Designer gave us an intricate and tough body and a wonderful vascular system. I pray for a wise and capable surgery team and a successful outcome. May you have patience and calmness after the procedure and may we hear from you soon. God bless and keep you safely in His palm.
Talon
Thanks Power...water means more to you when what sustains you comes from beneath your feet. Anavex means more than an investment to us when we realize what healing and joy it will bring. Think of a mom and dad upon hearing the first recognizable word from their two year old daughter!
My fellow posters/investors.....while we comment on the many aspects of our company and its share price, the brilliance or lack of it by our company's management and the market's infamous methodology, we must value the science and the millions whose lives and quality of, depends on it. Our investment is not in items or processes that are add-ons, but rather crucial drugs that are necessary for the quality of and the very essence of life. We pray that AVXL will benefit every sufferer of Alzheimer's, Parkinson's, Rett Syndrome, ALS, MS, Fragile X, Angleman's, Schizophrenia and many other terrible diseases.
Thanks for letting me give you a "pep talk"! And thanks to the men who gave my house water again, six days after our well died!
Shake It Up Australia Foundation is the grass routes organization for Parkinson's in Australia and is working closely with the MJFF on the next step in Parkinson's Disease research involving Anavex. "Parkinson's is the most common neurological disease in Australia behind dementia"
-----------
Shake It Up Australia Foundation <enquiries@shakeitup.org.au>
Great DD Nidan. While we heatedly discuss what is going on or not, Anavex keeps the trials rolling. Despite what are the difficult aspects of conducting clinical trials and data analysis during the last two year, we are gaining the "high ground". All the past conjecture will be gone with coming success.
Amen George..... for those who fought and still stand to protect us and our Democracy. May Anavex and its products do the same in protecting our health in the years to come. God Bless the USA
Pete....thankyou for the shares traded after hours and it was an honor.
As Lee Greenwood would say: God Bless the USA
https://www.bing.com/videos/search?&q=Lee+Greenwood+and+God+Bless+the+USA&view=detail&mid=DE6F042C94A84CC8D950DE6F042C94A84CC8D950&form=VDQVAP&ru=/search?q=Lee+Greenwood+and+God+Bless+the+USA&form=APMCS1&PC=APMC&adlt=strict&adlt=strict&ajaxhist=0&rvsmid=49C77D75D7807784459849C77D75D78077844598
How much of the stock traded hands "Afterhours"?
Nidan and Pete....you're both right on in this line of consideration.
The "prophylactic" possibilities of 2-73 have apparently increased with the worldwide COVID19 patients who may develop neurodegenerative side effects.
-----
https://www.biospace.com/article/research-suggests-covid-19-patients-at-higher-risk-of-parkinson-s-alzheimer-s-stroke-and-bleeding/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=217925041&_hsenc=p2ANqtz-9XBHLqyy0IZ3sylwaqSfquTG_GMKjHxLzGgrwu8zSFzjTpb6hpjopka91o3iWWU4ZJHLN0zQ5RBfiIpl-M-FhTPQTQow&utm_content=217925041&utm_source=hs_email
Biogen's Aduhelm continues to face an uphill struggle and in a statement at the middle of this article, so do all Alzheimer's drugs based on the "beta-amyloid" MOA.
---------
https://www.biospace.com/article/biogen-abandons-real-world-study-of-alzheimer-s-drug-aduhelm/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=217576545&_hsenc=p2ANqtz-9UltUJWeHMB6YVClHlYEKO9LKmwREfEdbxzkuZUDih4svRNGFj2criTkUirWj_kTyAtiXNNucVZQEXgrasmwNtChYThw&utm_content=217576545&utm_source=hs_email
Nidan/Xena....Good on ya!!
Biogen has all but given up on Aducanumab/Aduhelm after the medical community's negative evaluation and Medicare's restriction on its use. It would interesting to know the thoughts at the company post the desolved mutual investigation of 2-73 for MS. The process has cost the company its CEO and Chief Scientist.
The recriminations at Biogen will be immense when AVXL 2-73 is approved for Alzheimers.
----------------
https://www.fool.com/investing/2022/06/09/is-biogen-a-bargain-or-a-bust/?source=eptyholnk0000202&utm_source=yahoo- host&utm_medium=feed&utm_campaign=article
Consequences at Biogen.
Biogen CEO steps down after Aduhelm blunder—Chutes & Ladders
Biogen CEO steps down after a tumultuous year and bungled Aduhelm rollout.
Tred and Nidan....one of the problems of AVXL's valuation is the current WS view of the companies involved with the Alzheimer's drugs. When looking at the history of Biogen, Cassava and several others, investors are becoming conservative and demanding "show me" in this sector of biotech. A measured approach like Anavex's frustrates traders, but will pay investors in the course of 2-73/3-71's development.
More bad news for CASSAVA
----------------
https://www.biospace.com/article/another-journal-retracts-paper-co-authored-by-cassava-sciences-scientific-adviser/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=215206067&_hsenc=p2ANqtz-9T_16nZgXDPDoe40JH_v4F4EZFSSceM1oUR2_weX132SXKU5kNhb82tsxaFO9L9RoLpiE47COQooqpY6u7nRDzLDX3tA&utm_content=215206067&utm_source=hs_email
Thank you Power. My honor to stand with many others who consider it a solemn privilege to serve and protect their brothers and sisters of this great country.
Amen, Treden!
Treden...some new comments on M&A.
-------
https://www.biospace.com/article/biotechs-turn-to-m-and-a-as-liquidity-surges-and-market-caps-falter-/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=211020965&_hsenc=p2ANqtz-_O0duwclZcpeLmlqY5Fle7yir2EoAfz3U3tkVj-AWqZAkNhbpUzp8qcawoESeVYMeWtki7OfNtb-Qy00VABaA9epTu9Q&utm_content=211020965&utm_source=hs_email
Genentech....is reaching for an old bat in the Alzheimer's dugout as the amyloid plaque drugs continue to hope for gantenerumab's development based on the FDA/Biogen saga.
-----
https://www.fiercebiotech.com/biotech/20-years-genentech-persists-and-perseveres-alzheimers-gantenerumab?utm_source=email&utm_medium=email&utm_campaign=LS-NL-FierceBiotech+Tracker&oly_enc_id=6344A1822112C6Z
Correction: FXTAS not FAXAS
"FXTAS was discovered at the MIND Institute by researcher Randi Hagerman and her colleagues in 2001."
Chrismiss....having lived in Davis/Sacramento near UCD while flying C5's out of Travis AFB, I'm excited about Anavex working with Dr Randi Hagerman who heads the Mind Institute. That work involves the Rett trials and we hope the Fragile X/Faxas diseases which the Mind Institute is focused on presently. Since these are associated with the Autism family, future clinical trials with 2-73 may have a very broad scope. From her observations and comments about the efficacy of 2-73 in Rett Syndrome (she'd like to take it prophylactically for aging!), this is a very important association for Anavex.
Nidan....we private investors are not in control of stock pricing....who is? Just a simple comparison between Anavex and Cassava. Cassava has 40M shares outstanding and a market value 50% more than Anavex. Its price over 52 weeks $31.44 - $146.16. Look at the "Holder" information on Yahoo Finance ( quick comparison)....almost identical with the top Institutions (Black Rock, Vanguard, State Street, Goode Capital, Northern Trust, Susquehana, and Charles Schwab) as well as the Mutual Fund Holders. The shares held in Cassava are about half those held in Anavex ( probably because of the runaway price). Cassava has but one major drug, Sinufilam, which controversy over its data has forced it into another 78 week P3 trial stating last Nov. It is focusing on Alzheimers while Anavex has drug objectives with 273/371 for Alzhiemer's. Rett Syndrome. Parkinson's, Fragile X, Infintle Spasms,Angelmans, FD, ALS, Epilpsy and others. Who on WS is doing their home work...we shall see by the end of the year if hopefully not sooner.
Nidan.....AFFIRMATIVE!
Xena,,,,I've had hyaluronic acid shots for Knee pain (bone on bone) for about 5 years and it was very effective. I'm in the process of exchanging for new metal knees. With a shoulder replacement, I'm getting close to becoming a bionic investor!
Interesting article on CNS drug approval, somewhat based on the tribulation caused by Biogen and the FDA NDA process of Aducanumab. Ducks and data must be in line for future FDA submissions. Certainly why, with our FDA onboard experience, we are progressing very carefully in our drug development.
----
https://www.biospace.com/article/fda-briefing-documents-in-the-cns-space-have-investors-jittery/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsmi=208328707&_hsenc=p2ANqtz-_hgf7F9T3gKfNrtJyIP5BlAbMQR4ob7XWEAKXVPs9xWeSJicu0YdpUVKmYoF38vQd02V-D9V6E4ejPqVFyw35lFuzOqQ&utm_content=208328707&utm_source=hs_email
From the cited study....EUA application and future data.
----
"This data set and these trial results are the basis for an application for emergency use authorization.9 Collection of phase 2/3 data on vaccine immunogenicity and the durability of the immune response to immunization is ongoing, and those data are not reported here."
LBSR....you're right, except on how the clinical process has been maneuvered this is "off topic" and agree, let's move on.
Boi.....explain how the mechanism of "spike proteins" throughout the body is "gene spoofing". In layman's terms of course.
AAA..."If""
Xena....agree with you about the vaccines. The whole "Warp Speed" has been fought with poor adverse effect recording, a new vaccine methodology (mRNA) which is gene modification and a continual booster add-on with each new virus subtype. The facts are that the clinical process has been accelerated beyond the normal safety protocols. And if AVXL 2-73, which treats an equally deadly disease, was given the same FDA approval, we would be on the shelf today. The "COID Deaths" which have made Pfizer and Moderna $Billions have never made the distinction between "died with COVID and died because of COVID". The world medical community must do a thorough post epidemic review of how they handled COVID-19 or this debacle will happen again. MPO
Anavex on the MJFF website:
----
https://www.michaeljfox.org/search?query=Anavex
Fully agree with your last statement....the suffers of Alzheimer's need the best medical science from all sources.
Frrol....Take a look at both companies, their drugs, the number of diseases targeted and the progress of their clinical trials and tell me you would decide to pay $132 or even $14 for Annovis. No, I'm not in the least "suspicious" or "fearful" of forces in the market that are trying to direct stock direction!
Abew4me....again it is anyone person or group will pay more for a particular stock. You are saying that there are less investors in Annovis but they are willing to pay more than for Anavex. The stock's fortune has whipped it to over $130/share to where it is now at $14+. Something tells me the market is poor at evaluation or there are a number of manipulators on WS.
Interesting comparison with one of our competitors, Annovis. Our market cap is about 10X Annovis and our share volume today close to 100X times theirs....yet their share price was $14.18 (14.90AM) and ours $13.10 today. So much for market mechanics....anybody want to hazard an explanation?
This is an article where "solutions" are looking for "problems" i.e. BPharma, Biogen, Eisai, Lilly and Merck are seeking a broader definition of Alzheimer's which centers on the "plaque" approach rather than addressing "cognition improvement". It seems that the biomarkers surrounding plaque removal are not getting the validation that these companies"s drugs needs....so lets expand the science till it fits our needs.....do you hear us FDA and scientific experts?
----
https://www.fiercebiotech.com/medtech/drugmakers-unite-set-digital-standards-alzheimers-disease-studies
You are right Xena....I've read were the Black Rock CEO has thrown his weight on some very progressive issues where Black Rock was a very significant owner of a company's stock. Let's hope he isn't interested in influencing where the Alzheimer's/Dementia market is headed.
Our biggest institutional investor, Black Rock, may be looking for somewhere to put its Russian money.
---
https://www.marketwatch.com/story/the-worlds-largest-asset-manager-and-a-big-bond-fund-are-reported-to-be-early-losers-from-the-war-in-ukraine-11647117691?siteid=yhoof2